PharmAsia News India Pharma Roundup: Natco, Strides Arcolab, Glenmark, Ranbaxy/Pfizer, Merck
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Natco Pharmaceuticals said it is mulling its options after a court decision March 19 to allow Cipla to continue to make and sell Roche's lung cancer drug Tarceva (erlotinib) in India (PharmAsia News, March 20, 2008)
You may also be interested in...
Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer
NEW DELHI - A hostile bid by the world's largest drug maker Pfizer to thwart a deal for a majority stake by Japan's Daiichi Sankyo in India's top generic firm Ranbaxy Laboratories would likely be rebuffed by management led by the Singh family, which holds nearly 35 percent of the firm, analysts said
Analysts Say Ranbaxy Management Would Likely Rebuff Any Pfizer Offer
NEW DELHI - A hostile bid by the world's largest drug maker Pfizer to thwart a deal for a majority stake by Japan's Daiichi Sankyo in India's top generic firm Ranbaxy Laboratories would likely be rebuffed by management led by the Singh family, which holds nearly 35 percent of the firm, analysts said
India's Natco Will File India, Nepal Compulsory License Applications For Generic Versions Of Pfizer's Cancer Drug Celzentry
NEW DELHI - Natco Pharma told PharmAsia News it plans to file a compulsory license application to sell a generic version of Pfizer's HIV/AIDS drug Celzentry (maraviroc) in Nepal and India, the third such application by the firm, which has cited the high cost of the drugs to the patent office in India as the backbone of its cases
Need a specific report? 1000+ reports available
Buy Reports